Market research
EYE.AU Nova Eye Medical Limited
AU AUD Healthcare
Latest close
As of 30 Oct 2026
Test a moving-average rule with historical data.
Market facts
- P/E ratio
- Not available
- Analyst target
- 0.425
- Dividend yield
- Not available
- Beta
- 0.93
Profile
Instrument facts
- Exchange
- AU
- Currency
- AUD
- Sector
- Healthcare
- Industry
- Medical Devices
- ISIN
- AU0000094252
- P/E ratio
- Not available
- Analyst target
- 0.425
- Dividend yield
- Not available
- Beta
- 0.93
About
About Nova Eye Medical Limited
Nova Eye Medical Limited designs, develops, manufactures, markets, and sells surgical devices for the treatment of glaucoma in Australia, the United States, Europe, the Asia Pacific, and internationally. The company operates through Glaucoma Surgical Devices and AlphaRET segments. It offers 2RT, a proprietary laser technology to treat patients in early and intermediate age-related macular degeneration for the treatment of retinal disease. The company offers iTrack, a glaucoma surgical device to reduce intraocular pressure in patients glaucoma; iTrack Advance; and Molteno3, a glaucoma drainage device to treat patients with severe or complex glaucoma. The company was formerly known as Ellex Medical Lasers Limited and changed its name to Nova Eye Medical Limited in July 2020. Nova Eye Medical Limited was incorporated in 1970 and is headquartered in Kent Town, Australia.
Research context
Nova Eye Medical Limited appears in PyInvesting’s Australia Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- AUD
- Sector
- Healthcare
- Industry
- Medical Devices
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the EYE.AU discussion.
5 years, 6 months ago
Nova Eye Medical Limited is currently in a long term downtrend where the price is trading 4.9% below its 200 day moving average.
From a valuation standpoint, the stock is 98.4% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 4.1.
Nova Eye Medical Limited's total revenue sank by 8.5% to $7M since the same quarter in the previous year.
Its net income has increased by 40.1% to $-2M since the same quarter in the previous year.
Finally, its free cash flow fell by 577.6% to $-2M since the same quarter in the previous year.
Based on the above factors, Nova Eye Medical Limited gets an overall score of 2/5.